Total Payments
$509,824
2024 Payments
$2,524
Companies
10
Transactions
217
Payment Breakdown by Category
Research$479,269 (94.0%)
Travel$18,876 (3.7%)
Consulting$9,000 (1.8%)
Food & Beverage$2,678 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $479,269 | 132 | 94.0% |
| Travel and Lodging | $18,876 | 36 | 3.7% |
| Consulting Fee | $9,000 | 1 | 1.8% |
| Food and Beverage | $2,678 | 48 | 0.5% |
Payments by Type
Research
$479,269
132 transactions
General
$30,555
85 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $205,078 | 109 | $0 (2019) |
| Ichnos Sciences Inc. | $203,036 | 8 | $0 (2022) |
| Bausch Health US, LLC | $69,932 | 6 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $14,206 | 37 | $0 (2024) |
| AstraZeneca AB | $10,867 | 7 | $0 (2019) |
| AstraZeneca UK Limited | $2,406 | 18 | $0 (2019) |
| Merck Sharp & Dohme LLC | $1,683 | 15 | $0 (2024) |
| Shionogi Inc | $1,348 | 7 | $0 (2017) |
| SANOFI US SERVICES INC. | $1,129 | 6 | $0 (2024) |
| AbbVie, Inc. | $140.00 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,524 | 16 | AstraZeneca Pharmaceuticals LP ($1,361) |
| 2023 | $4,075 | 30 | AstraZeneca Pharmaceuticals LP ($2,561) |
| 2022 | $62,092 | 8 | Bausch Health US, LLC ($52,877) |
| 2021 | $51,421 | 3 | Ichnos Sciences Inc. ($51,376) |
| 2020 | $142,579 | 5 | Ichnos Sciences Inc. ($142,579) |
| 2019 | $200,930 | 99 | Glenmark Pharmaceuticals Inc. ($161,647) |
| 2018 | $44,855 | 49 | Glenmark Pharmaceuticals Inc. ($43,430) |
| 2017 | $1,348 | 7 | Shionogi Inc ($1,348) |
All Payment Transactions
217 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $401.52 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $311.37 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $253.09 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $125.00 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $59.99 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.50 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.50 | General |
| 06/26/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/27/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $517.54 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/27/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $435.93 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/26/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $75.08 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/26/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $50.21 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/26/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/26/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 07/15/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $86.25 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $78.30 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $54.00 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $40.50 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $35.10 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Respiratory | ||||||
| 07/13/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $523.18 | General |
| Category: Respiratory | ||||||
| 07/13/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $230.34 | General |
| Category: Respiratory | ||||||
| 07/13/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $172.50 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GBR830-204 | Ichnos Sciences Inc. | $193,955 | 7 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $161,647 | 72 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $52,877 | 4 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $43,430 | 37 |
| A Randomized, Double-blind, Placebo-controlled, 3 Dose Level, Parallel Group Study of the Efficacy and Safety of Plecanatide in Adolescents 12 to 18 Years of Age With Chronic Idiopathic Constipation CIC | Bausch Health US, LLC | $17,010 | 1 |
| ISB830-204 | Ichnos Sciences Inc. | $9,081 | 1 |
| Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $1,129 | 6 |
About Dr. Sady Alpizar, MD
Dr. Sady Alpizar, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013109958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sady Alpizar, MD has received a total of $509,824 in payments from pharmaceutical and medical device companies, with $2,524 received in 2024. These payments were reported across 217 transactions from 10 companies. The most common payment nature is "" ($479,269).
Ad
Practice Information
- Specialty Internal Medicine
- Location Tampa, FL
- Active Since 08/14/2007
- Last Updated 05/23/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1013109958
Products in Payments
- GBR830-204 (Drug) $142,579
- TRULANCE (Drug) $17,010
- BREZTRI (Drug) $2,561
- FASENRA (Drug) $1,386
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Internal Medicine $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Internal Medicine $562,511
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Internal Medicine $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357
Internal Medicine $273,357
Mayer Fishman, Md, MD
Internal Medicine — Payments: $270,522
Internal Medicine $270,522